Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7607650 | 0.88 | HRH2 (0.41) | HRH2HRH1SIGMAR1CXCR4HRH3 | |
| SCHEMBL3850949 | 0.82 | SIGMAR1 (0.49) | SIGMAR1CXCR4MEN1KMT2AALDH1A1 | |
| SCHEMBL8187485 | 0.75 | CXCR4 (0.59) | SIGMAR1CXCR4SMN1; SMN2PAOX | |
| SCHEMBL6645511 | 0.75 | CXCR4 (0.57) | SIGMAR1CXCR4ALDH1A1SMN1; SMN2PAOX | |
| SCHEMBL2621583 | 0.74 | SMN1; SMN2 (0.49) | HRH2HRH1SIGMAR1CXCR4HRH3 | |
| SCHEMBL5265735 | 0.73 | HRH3 (0.46) | HRH3MEN1KMT2AMAPT | |
| SCHEMBL7607654 | 0.72 | HRH2 (0.38) | HRH2HRH1SIGMAR1CXCR4HRH3 | |
| SCHEMBL7161461 | 0.72 | HRH3 (0.42) | HRH2HRH1SIGMAR1CXCR4HRH3 | |
| SCHEMBL21120474 | 0.72 | HRH2 (0.47) | HRH2HRH1SIGMAR1CXCR4HRH3 | |
| SCHEMBL21348722 | 0.72 | HRH2 (0.47) | HRH2HRH1SIGMAR1CXCR4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | disclosed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | HRH2 905/4885HRH1 1260/4885SIGMAR1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.